Nt-ProBNP Discriminatory Role Between Symptomatic and Asymptomatic Patients with Severe Valvular Aortic Stenosis

1. Vahanian A, Alfieri O, Andreotti F et al. The Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Guidelines for the management of valvular heart disease (version 2012). European Heart Journal 2012; 33: 2451-2496.10.1093/eurheartj/ehs109Search in Google Scholar

2. Baumgartner H, Falk V, Bax JJ, et al. ESC/EACTS Guidelines for the management of valvular heart disease, European Heart Journal 2017; 38: 2739-279110.1093/eurheartj/ehx391Open DOISearch in Google Scholar

3. Bonow RO, Carabello BA, Chatterjee K, et al. American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2008 focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease, J Am Coll Cardiol 2008; 52: 1-142.Search in Google Scholar

4. Schiller NB, Shah PM, Crawford M et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography: American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr 1989; 2: 358-367.10.1016/S0894-7317(89)80014-8Search in Google Scholar

5. Popescu BA, Andrade MJ, Badano LP, et al. European Association of Echocardiography recommendations for training, competence, and quality improvement in echocardiography. Eur J Echo-cardiogr 2009; 10: 893-905.10.1093/ejechocard/jep15119889658Search in Google Scholar

6. Baumgartner H, Hung J, Bermejo J, et al. Echo-cardiographic assessment of valve stenosis: EAE/ASE recommendations for clinical practice. Eur J Echocardiogr 2009; 10: 1-25.10.1093/ejechocard/jen30319065003Open DOISearch in Google Scholar

7. Rosenhek R, Maurer G, Baumgartner H. Should early elective surgery be performed in patients with severe but asymptomatic aortic stenosis. EHJ 2002; 23: 1417-1421.10.1053/euhj.2002.316312208221Search in Google Scholar

8. Struthers AD. Ten years of natriuretic peptide research: a new dawn for their diagnostic and therapeutic use. BMJ 1994; 308: 1615-9.10.1136/bmj.308.6944.161525404318025431Search in Google Scholar

9. Buckley MG, Marcus NJ, Yacoub MH et al. Prolonged stability of BNP: importance for non-invasive assessment of cardiac function in clinical practice. Clin Sci 1998;95:235-9.10.1042/CS19980045Search in Google Scholar

10. Roche Diagnostics. Pro-Brain natriuretic peptide package insert. Indianapolis 2002; Roche Diagnostics.Search in Google Scholar

11. Kazanegra R, Cheng V, Garcia A, et al. A rapid test for B-type natriuretic peptide correlates with falling wedge pressures in patients treated for de-compensated heart failure: a pilot study. J Card Fail 2001; 7: 21-9.10.1054/jcaf.2001.2335511264546Search in Google Scholar

12. Qi W, Mathisen P, Kjekshus J, et al. Natriuretic peptides in patients with aortic stenosis. Am Heart J 2001; 142: 725-32.10.1067/mhj.2001.11713111579366Search in Google Scholar

13. Salehian O, Chan LK. Should brain natriuretic peptides be measured in patients with aortic valve disease. Eur H J 2005; 26: 951-952.10.1093/eurheartj/ehi21615781430Search in Google Scholar

14. Baumgartner H. Aortic stenosis: medical and surgical management, Heart 2005; 91: 1483-1488.10.1136/hrt.2004.056176176917616230456Open DOISearch in Google Scholar

15. Gerber IL, Stewart RA, Legget ME, et al. Increased plasma natriuretic peptide levels reflect symptom onset in aortic stenosis. Circulation. 2003; 107: 1884-1890.10.1161/01.CIR.0000060533.79248.0C12668523Search in Google Scholar

16. Lim P, Monin LJ, Monchi M, et al. Predictors of outcome in patients with severe aortic stenosis and normal left ventricular function: role of B-type natriuretic peptide. Eur H J. 2004; 25: 2048-2053.10.1016/j.ehj.2004.09.03315541842Search in Google Scholar

17. Bergler-Klein J, Klaar U, Heger M, et al. Natriuretic peptides predict symptom-free survival and postoperative outcome in severe aortic stenosis. Circulation. 2004; 109: 2302-2308.10.1161/01.CIR.0000126825.50903.1815117847Search in Google Scholar

18. Weber M, Arnold R, Rau M, et al. Relation of N-terminal pro B-type natriuretic peptide to progression of aortic valve disease. Eur H J 2005; 26: 1023-1030.10.1093/eurheartj/ehi23615781428Search in Google Scholar

19. Weber M, Hausen M, Arnold R, et al. Prognostic value of N-terminal pro-B-type natriuretic peptide for conservatively and surgically treated patients with aortic valve stenosis. Heart 2006; 92: 1639-1644.10.1136/hrt.2005.085506186121216740919Open DOISearch in Google Scholar

20. Otto Catherine M, FACC. Valvular aortic stenosis: disease severity and timing of intervention. J Am Coll Cardiol 2006; 47: 2141-51.10.1016/j.jacc.2006.03.00216750677Open DOISearch in Google Scholar

21. Vahanian A, Otto CM. Risk stratification of patients with aortic stenosis. European Heart Journal (2010)31, 416-42310.1093/eurheartj/ehp57520047994Open DOISearch in Google Scholar

22. Parikh V, Kim C, Robert J. et al. Natriuretic peptides for risk stratification of patients with valvular Aortic Stenosis, Circ Heart Fail. 2015; 8: 373-380.Search in Google Scholar